Estrogen plus progestin and the risk of coronary heart disease.

By JoAnn E. Manson, J. Hsia, K. Johnson, J. Rossouw, A. Assaf, N. Lasser, M. Trevisan, H. Black, S. Heckbert, R. Detrano and 5 more. New England Journal of Medicine, 2003

2,059 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Genetics

View Paper: https://www.semanticscholar.org/paper/3532fe4bf80e2c8f1c44ddbfd60fc75d9aab7443

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. W. Willett
2. JoAnn E. Manson
3. Miguel A. Hern'an
4. MR Stampfer
5. Marja-Riitta Taskinen
6. I. Graham
7. R. Logan
8. James M. Robins

In Genetics

1. Miguel A. Hern'an
2. Marja-Riitta Taskinen
3. Karin B. Michels
4. B. Ference
5. Peter J. Schmidt

Citations in the corpus

• 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. (2019, background): “Oestrogen replacement therapy, despite some favourable effects on lipid profiles, has not been demonstrated to reduce CV risk and cannot be recommended for CVD prevention in women.(392) No lipid-lowering drugs should be administered during pregnancy and the period of breastfeeding because data on po”
• [Guidelines on the management of stable angina pectoris: executive summary]. (2006, background): “Primary prevention with unopposed estrogen therapy in hysterectomized women offered no cardiovascular protection.(177) New guidelines therefore recommend against routine use of HRT for chronic conditions(178) and current users have been advised to taper doses downwards towards discontinuation.”
• 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. (2016, background): “Oestrogen replacement therapy, despite some favourable effects on the lipid profile, has not been demonstrated to reduce CV risk and cannot be recommended for CVD prevention in women.(318) No lipid-lowering drugs should be administered during pregnancy and the period of breastfeeding since data on p”
• Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease (2008, background): “6 years).(8,9) The present paper does not address the complex clinical and public health issues related to hormone therapy, including risk-benefit considerations.”